We performed a pooled analysis to assess the different efficacy of PD-1/PD-L1 inhibitor therapy, including mono- or combined therapy, in both HBV+ HCC and HBV− HCC patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.